The cardiac dysfunction caused by sepsis in animals with chronic kidney disease is attenuated by inhibiting I kappa B kinase

This is a pre print version of the following article:

Original Citation:

Availability:
This version is available http://hdl.handle.net/2318/1522574 since 2015-08-07T14:34:50Z

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
THE CARDIAC DYSFUNCTION CAUSED BY SEPSIS IN ANIMALS WITH CHRONIC KIDNEY DISEASE IS ATTENUATED BY INHIBITING I.B KINASE

J. Chen1, J. Kieswich1, F. Chiazza2, T. Gobbetti1, N.S. Patel1, M. Perretti1, M. Collino2, M.M. Yaqoob1, and C. Thiemermann*1.

1Queen Mary University of London, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, London, United Kingdom, 2University of Turin, Department of Drug Science and Technology, Turin, Italy

Patients with chronic kidney disease (CKD) requiring dialysis have a higher risk of sepsis and a 100-fold higher mortality than the general population with sepsis. The severity of cardiac dysfunction is an important predictor of mortality among patients with sepsis. Having discovered that pre-existing CKD worsens the cardiac outcome in mice with sepsis (1), we have investigated whether inhibition of I.B kinase (IKK) reduces the cardiac dysfunction in these animals.

Male C57BL/6 mice were subjected to a two-stage, 5/6th nephrectomy (SNX). After 8 weeks, mice with SNX/CKD were subjected to either low dose LPS (2mg/kg) or cecum ligation and puncture (CLP) (fluid and antibiotics given at 6h and 18h after CLP). At 18h after LPS injection or 24h after CLP, cardiac function was evaluated by echocardiography. When compared to sham mice, SNX for 8 weeks resulted in a significant rise in urea and creatinine and a small (PG0.05) reduction in ejection fraction (EF). In sham mice without CKD, low dose LPS or CLP had no effect on EF, lung myeloperoxidase (MPO) activity or systemic cytokine levels. In CKD mice, LPS or CLP caused profound cardiac dysfunction (Fig. 1A), increased lung MPO activity and increased plasma cytokine levels (TNF-, IL-1", IL-6, IL-10). Compared with sham mice, cardiac biopsies obtained from CKD mice showed increases in the phosphorylation of IkBα, nuclear translocation of the NF-kB subunit p65, increased iNOS expression, and significant increases in phosphorylation of Akt and ERK1/2. Moreover in CKD mice, LPS or CLP further increased the phosphorylation of IkBα, the nuclear translocation of p65 and the iNOS expression. Treatment of CKD mice with the IKK inhibitor IKK 16 (1 mg/kg, 1 h after CLP) attenuated cardiac dysfunction (Fig. 1B), increase in lungMPO activityand cytokine formation caused by CLP. IKK 16 also reduced the i) increased phosphorylation of IKBα; ii) increased nuclear translocation of p65; and iii) significant increase in iNOS expression in CKD hearts subject to CLP. In conclusion, the presence of CKD aggravates the cardiac dysfunction caused by LPS or CLP in the mouse; and this may (at least in part) be due to increased cardiac activation of NF-κB and increased iNOS expression.

(1) Chen et al, Shock 2014;41(Supplement 2):40